Get the Stockscreener App
0.00
100.00%
-221.38
Cidara Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
See More
Previous Close:
$221.38
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$6.96B
Revenue:
$302.00K
Net Income/Loss:
$-117.10M
P/E Ratio:
0.00
EPS:
-11.13
Net Cash Flow:
$-129.13M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$221.42
Cidara Therapeutics Inc Stock (CDTX) Company Profile
Name
Cidara Therapeutics Inc
Sector
Industry
Phone
858-752-6170
Address
6310 NANCY RIDGE DRIVE, SAN DIEGO, CA
Compare CDTX vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDTX
Cidara Therapeutics Inc
|
0.00 | 6.96B | 302.00K | -117.10M | -129.13M | -11.13 |
VRTX
Vertex Pharmaceuticals Inc
|
446.54 | 113.44B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
772.64 | 81.68B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
730.25 | 45.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.87 | 43.88B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.52 | 35.25B | 606.42M | -1.28B | -997.58M | -6.403 |
Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-17-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-17-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-17-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-16-25 | Initiated | Morgan Stanley | Overweight |
| Oct-10-25 | Initiated | JP Morgan | Overweight |
| Jun-18-25 | Resumed | H.C. Wainwright | Buy |
| Mar-12-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jan-27-25 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Nov-08-24 | Initiated | Guggenheim | Buy |
| Aug-14-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-03-21 | Resumed | H.C. Wainwright | Buy |
| Sep-22-21 | Upgrade | WBB Securities | Buy → Strong Buy |
| Mar-04-21 | Initiated | Aegis Capital | Buy |
| Sep-04-19 | Upgrade | Wedbush | Neutral → Outperform |
| Jul-26-18 | Initiated | Citigroup | Buy |
| Apr-21-17 | Initiated | Raymond James | Strong Buy |
| Apr-17-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-12-17 | Initiated | Ladenburg Thalmann | Buy |
| Apr-11-17 | Resumed | Wedbush | Outperform |
| Feb-22-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-17 | Upgrade | WBB Securities | Sell → Hold |
| Dec-21-16 | Resumed | Leerink Partners | Outperform |
| Dec-19-16 | Initiated | H.C. Wainwright | Buy |
| Sep-23-16 | Downgrade | WBB Securities | Hold → Sell |
| Oct-09-15 | Upgrade | WBB Securities | Sell → Hold |
| May-11-15 | Initiated | Jefferies | Buy |
| May-11-15 | Initiated | Leerink Partners | Outperform |
| May-11-15 | Initiated | Needham | Buy |
| May-11-15 | Initiated | Wedbush | Outperform |
| Apr-23-15 | Initiated | WBB Securities | Sell |
View All
Cidara Therapeutics Inc Stock (CDTX) Latest News
HC Wainwright & Co. Maintains Cidara Therapeutics (CDTX) Buy Recommendation - MSN
Cidara Therapeutics (CDTX) Price Target Increased by 77.93% to 134.30 - MSN
Cidara Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | | US1717572069 - marketscreener.com
Gainers Report: Will Cidara Therapeutics Inc outperform during market ralliesNew Guidance & Proven Capital Preservation Tips - baoquankhu1.vn
Morgan Stanley Initiates Coverage of Cidara Therapeutics (CDTX) with Overweight Recommendation - MSN
Superstring Capital's New Axsome Therapeutics Position: A $6.84M Biopharma InvestmentNews and Statistics - IndexBox
Merck completes purchase of biopharma company making experimental flu drug - WFMZ.com
Cidara Therapeutics (CDTX) Price Target Increased by 24.94% to 167.79 - MSN
CDTX SEC FilingsCidara Theraptcs 10-K, 10-Q, 8-K Forms - Stock Titan
Breakout Move: Will Cidara Therapeutics Inc outperform during market rallies2026 Retail Activity & Precise Swing Trade Alerts - baoquankhu1.vn
RedChip Companies Congratulates Former Client Cidara Therapeutics on Its $9.2 Billion Acquisition by Merck - The Coloradoan
Patterns Watch: Can Cidara Therapeutics Inc sustain its profitabilityEarnings Miss & Smart Allocation Stock Tips - baoquankhu1.vn
Why Cidara Therapeutics Inc. stock could see breakout soonWeekly Market Outlook & High Accuracy Swing Trade Signals - Naître et grandir
Baron Health Care Fund adds TMO, ARQT, and ELAN; exits Cidara Therapeutics, MASI among Q4 moves - MSN
Cidara (CDTX) Climbs 105% on $9.2-Billion Merger with Merck - MSN
Cidara Therapeutics Stock Rockets Over 700% This Year — Then Wall Street Turns Neutral On Merck Takeover - Stocktwits
Baron Health Care Fund Q4 2025 Contributors And Detractors - Seeking Alpha
Cidara Therapeutics, Inc. (CDTX) Stock Analysis: Is This Biotech Pioneer Poised for Growth? - DirectorsTalk Interviews
Cidara Therapeutics announces inclusion in the Russell 2000 and 3000 indexes - MSN
Block Trades: Is Cidara Therapeutics Inc benefiting from innovation trendsMarket Performance Report & Daily Stock Trend Watchlist - baoquankhu1.vn
Cidara Therapeutics, Inc. (CDTX) Stock Report: Navigating a Biotech Trail with a Market Cap of $6.96 Billion - DirectorsTalk Interviews
Point72 entities disclose 1.4% Cidara Therapeutics (CDTX) stake in Schedule 13G/A - Stock Titan
Can Cidara Therapeutics Inc. sustain its profitabilityJuly 2025 Highlights & Low Risk High Reward Ideas - mfd.ru
Is Cidara Therapeutics Inc. being accumulated by smart money - mfd.ru
Is Cidara Therapeutics Inc. stock dividend yield sustainableJuly 2025 Gainers & Free Expert Approved Momentum Trade Ideas - mfd.ru
How cyclical is Cidara Therapeutics Inc.’s revenue streamIPO Watch & Stepwise Trade Execution Plans - mfd.ru
Vivo Opportunity funds exit Cidara Therapeutics (CDTX) after merger completion - Stock Titan
Is Cidara Therapeutics Inc. benefiting from innovation trendsWeekly Trade Review & Weekly High Potential Stock Alerts - mfd.ru
RedChip Fintech & DATS Conference Replays Now Available Featuring Public Companies Shaping the Future of Digital Finance - USA Today
Merck Completes Tender Offer and Moves to Acquire Cidara Therapeutics - The Healthcare Technology Report.
Merck & Co., Inc. Q4 Earnings Call Highlights - MarketBeat
Portfolio Recap: How sensitive is Cidara Therapeutics Inc to inflationTrade Ideas & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Merck (MRK) Faces One-Time Charge Due to Cidara Acquisition - GuruFocus
Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline - Business Wire
Aug Highlights: How sensitive is Cidara Therapeutics Inc to inflationQuarterly Investment Review & Free High Return Stock Watch Alerts - baoquankhu1.vn
Biotech Stocks Worth WatchingJanuary 8th - MarketBeat
Top Biotech Stocks To Watch NowJanuary 2nd - MarketBeat
Cidara Therapeutics, Inc. (CDTX) Stock Analysis: Understanding the Dynamics of a $6.96 Billion Biotech - DirectorsTalk Interviews
Is Cidara Therapeutics Inc. on track to beat earnings2025 Pullback Review & Entry and Exit Point Strategies - Mfd.ru
Published on: 2026-01-28 17:40:21 - mfd.ru
Promising Biotech Stocks To ConsiderJanuary 4th - MarketBeat
Pharma News: What is the earnings history of Cidara Therapeutics IncWeekly Risk Report & Low Volatility Stock Recommendations - baoquankhu1.vn
Biotech Stocks To Add to Your WatchlistJanuary 7th - MarketBeat
Cidara Therapeutics, Inc. (CDTX) Stock Analysis: Navigating the Biotech Landscape with Potential Upside - DirectorsTalk Interviews
Biotech Stocks To Follow NowJanuary 5th - MarketBeat
Weekly Earnings: Is Cidara Therapeutics Inc benefiting from innovation trends2025 Key Lessons & High Conviction Trade Alerts - baoquankhu1.vn
Best Biotech Stocks To Keep An Eye OnJanuary 14th - MarketBeat
Support Test: Will Cidara Therapeutics Inc stock benefit from upcoming earnings reportsJuly 2025 Movers & Fast Entry Momentum Trade Alerts - Bộ Nội Vụ
Whale Trades: Will Cidara Therapeutics Inc. stock benefit from upcoming earnings reportsTrade Analysis Summary & Verified Swing Trading Watchlists - moha.gov.vn
This Biotech's Stock Price More Than Doubled on Friday. Here's Why. - MSN
Biotech Stocks To ConsiderJanuary 12th - MarketBeat
Cidara Therapeutics Inc Stock (CDTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):